Acta Clinica Belgica最新文献

{"title":"Personalized antiplatelet therapy: a scoping review on the role of platelet function testing and genotyping in acute coronary syndrome.","authors":"Jeenal Venissa Rebello, Ashna Shah, Mohammed Salim Karattuthodi, Chun-Wai Mai, Mohamed Hassan Elnaem","doi":"10.1080/17843286.2026.2653688","DOIUrl":"10.1080/17843286.2026.2653688","url":null,"abstract":"<p><strong>Background: </strong>Acute coronary syndrome (ACS) remains a leading cause of global morbidity and mortality, often managed with antiplatelet therapy. However, variability in patient response due to comorbidities, genetic polymorphisms, and resistance to antiplatelet agents creates challenges in optimizing treatment.</p><p><strong>Methods: </strong>The scoping review was conducted using Arksey and O'Malley's five-step framework to identify facilitators and challenges influencing the use of Platelet Function Test (PFT) and genotype-guided antiplatelet therapy for ACS. PubMed, Embase, and Scopus were utilized for identifying the relevant articles published between 2010 and 2025.</p><p><strong>Results: </strong>A total of 346 studies was included, with sample sizes ranging from 13 to 10,048 patients. The included studies showed heterogeneity in study design, sample size, follow-ups, PFT techniques and in outcomes. The articles had predominantly male patients with various comorbidities. The PFTs identified included VerifyNow, light transmission aggregometry (LTA), vasodilator-stimulated phosphoprotein (VASP), multiplate, thromboelastography (TEG) etc. The facilitating factors for PFT included risk stratification for bleeding and ischemic events and treatment adjustments in high-risk groups. Whereas the key challenges identified were lack of assay standardization, discordance between test results, and variability across testing modalities. Although the association between treatment response and genetic polymorphisms were frequently reported, evidence for clinical outcome remains variable and uncertain.</p><p><strong>Conclusion: </strong>Existing evidence shows that PFT and genotyping may provide significant findings for tailoring antiplatelet therapy in ACS. However the heterogeneity and practical challenges limit their routine use. Further, well-designed outcome driven studies and standardised protocols are required to define their role in precision guided therapy for ACS management.</p>","PeriodicalId":48865,"journal":{"name":"Acta Clinica Belgica","volume":" ","pages":"347-360"},"PeriodicalIF":1.4,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147724234","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Hospital-based identification and preparation of a personalized tapering program for long-term hypnosedative use in older adults with insomnia: feasibility and barriers.","authors":"Ine Simal, Omy Vanneste, Andreas Capiau, Mirko Petrovic, An Mariman, Koen Boussery, Annemie Somers","doi":"10.1080/17843286.2026.2711891","DOIUrl":"https://doi.org/10.1080/17843286.2026.2711891","url":null,"abstract":"<p><strong>Objectives: </strong>This pilot study evaluated the feasibility of hospital-based identification and preparation for a personalised, multidisciplinary tapering programme for long-term hypnosedative use in older adults with insomnia, focusing on implementation processes and patient-reported barriers rather than clinical efficacy.</p><p><strong>Methods: </strong>This single-centre, prospective, interventional pilot study was conducted at Ghent University Hospital (Belgium). Patients aged ≥70 years using ≥1 hypnosedative for insomnia for ≥90 consecutive days were screened. Eligible participants received either a reimbursed tapering scheme or an individual tapering plan which was initiated after discharge. Both were developed collaboratively with the patient, hospital physicians, clinical pharmacist, general practitioner, and community pharmacist. Follow-up telephone interviews at four and twelve weeks assessed tapering adherence, self-reported barriers, fall incidents, and sleep quality.</p><p><strong>Results: </strong>Among 2860 screened patients, 30 were included (median age 77 years; 50% Male; 93.3% polypharmacy). At 12 weeks, 23.1% were actively tapering, and 19.2% had fully discontinued hypnosedatives. The most frequently reported barriers involved reflective motivation (62.9%), including (fear of) worsening sleep and deterioration in physical or mental health. Social opportunity barriers (22.8%) included limited support from healthcare professionals. Structural barriers included missing prescriptions and incomplete discharge instructions.</p><p><strong>Conclusion: </strong>Deprescribing hypnosedatives in older patients within a hospital setting is complex and challenged by low recruitment, motivational, social, and structural barriers. Multidisciplinary strategies, education, and integrated care pathways are essential to enhance implementation. Policy measures, including broader reimbursement and shared electronic medication records could further facilitate safe deprescribing interventions.</p>","PeriodicalId":48865,"journal":{"name":"Acta Clinica Belgica","volume":" ","pages":"1-12"},"PeriodicalIF":1.4,"publicationDate":"2026-07-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148632353","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Guidance on Belgian referral criteria for lung volume reduction and lung transplantation in patients with severe emphysema-COPD.","authors":"Olivier Taton, Eric Marchand, Francois M Carlier, Kris Carron, Laurens J Ceulemans, Wim Janssens, Maarten Vander Kuylen, Robin Vos, Reinier Wener, Geert Verleden, Stephanie Everaerts","doi":"10.1080/17843286.2026.2711066","DOIUrl":"https://doi.org/10.1080/17843286.2026.2711066","url":null,"abstract":"<p><strong>Background: </strong>Chronic obstructive pulmonary disease (COPD) is characterized by persistent airflow limitation and represents a major global public health burden. Despite optimized guideline-based pharmacological and non-pharmacological management, many patients remain highly symptomatic, largely due to emphysema-related lung hyperinflation. Hyperinflation plays a central role in the pathophysiology of dyspnea and exercise intolerance and is more closely associated with symptom severity and functional impairment than airflow obstruction alone, making it a key therapeutic target in advanced COPD.</p><p><strong>Objectives: </strong>To provide simplified and context-specific referral criteria for lung volume reduction and lung transplantation (LTx) in Belgian patients with severe COPD and emphysema, with the aim of facilitating timely identification and referral of eligible patients to specialized centers.</p><p><strong>Methods: </strong>This guidance document was developed by experts of the Belgian Respiratory Society, taking into consideration evidence on lung volume reduction strategies, including lung volume reduction surgery (LVRS) and endoscopic lung volume reduction (ELVR), as well as LTx, and the specific requirements of the Belgian healthcare system, including national reimbursement criteria for ELVR.</p><p><strong>Results: </strong>Lung volume reduction strategies and LTx have demonstrated clinically meaningful improvements in selected patients with severe emphysema. However, access to these interventions remains suboptimal in Belgium, with national registry data indicating substantial under-referral to specialized centers compared with neighboring countries. The proposed recommendations emphasize early referral to prevent irreversible physiological decline, optimize patient selection, facilitate multidisciplinary evaluation, and improve procedural and long-term outcomes.</p><p><strong>Conclusions: </strong>This standardized, evidence-based referral framework, tailored to the Belgian healthcare system, aims to improve access to advanced interventional therapies for patients with severe COPD and emphysema. Timely referral and appropriate multidisciplinary assessment may ultimately improve functional outcomes, quality of life, and survival in eligible patients.</p>","PeriodicalId":48865,"journal":{"name":"Acta Clinica Belgica","volume":" ","pages":"1-10"},"PeriodicalIF":1.4,"publicationDate":"2026-07-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148622167","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"An explainable machine learning approach for cervical cancer screening: decoding morphological diagnostic drivers.","authors":"Huan Chang, Xiaoxu Liu, Lixin Qin, Yafan Wang, Limei Mao, Donghua Wang, Jianwei Zhang, Xiaoqing Pang","doi":"10.1080/17843286.2026.2711062","DOIUrl":"https://doi.org/10.1080/17843286.2026.2711062","url":null,"abstract":"<p><strong>Background: </strong>Cervical cancer screening in primary care is hindered by expert pathologist shortages and heavy diagnostic workloads, leading to fatigue-induced misdiagnoses. This study evaluated the diagnostic capacity, subpopulation robustness, and operational efficiency of an interpretable machine learning (ML) tool within a large Chinese healthcare network.</p><p><strong>Methods: </strong>A retrospective database of 5,000 women was audited. Archived liquid-based cytology (LBC) digital slides were evaluated via a parallel validation channel: the LBC-NET pipeline versus a double-blind panel of senior cytopathologists. Diagnostic safety was tested by stratifying data across age, vaginal infections, and menopause conditions. Algorithmic transparency was quantified using game-theoretic Shapley Additive exPlanations (SHAP) and morphological feature tracking. Operational efficiency was evaluated via continuous cumulative distribution curves.</p><p><strong>Results: </strong>For detecting high-grade squamous intraepithelial lesions or worse (HSIL+), the ML model achieved a clinical sensitivity of 92.5%, significantly outperforming the manual method at 84.2% (<i>p</i> < 0.001), with an area under the curve (AUC) of 0.94. Subgroup stratification demonstrated that menopausal tissue atrophy or active vaginal infections caused no significant performance degradation (<i>p</i> > 0.05). SHAP analytics revealed that the nucleus-to-cytoplasmic ratio and nuclear hyperchromasia intensity were the core predictive metrics. Operationally, the ML system compressed the median slide-review time by 63.0%, escalating the daily screening capacity by 175% and reducing specialist referral consultations by 45.2%.</p><p><strong>Conclusion: </strong>The interpretable ML tool provides a reliable and fast clinical choice for massive cervical cancer screening.</p>","PeriodicalId":48865,"journal":{"name":"Acta Clinica Belgica","volume":" ","pages":"1-13"},"PeriodicalIF":1.4,"publicationDate":"2026-07-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148609045","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Belgian consensus-based recommendations on the management of hospitalized patients with a penicillin allergy label.","authors":"Rik Schrijvers, Janneke Cox, Françoise Pirson, Alessandro Toscano, Greet Van De Sijpe, Xavier Van der Brempt, Mathilde Berghmans, Bénédicte Delaere, Frederique Jacobs, Jan Vancauwenberghe","doi":"10.1080/17843286.2026.2708796","DOIUrl":"https://doi.org/10.1080/17843286.2026.2708796","url":null,"abstract":"<p><strong>Objectives: </strong>Penicillin allergy labels are common among hospitalized adults and are frequently inaccurate, potentially leading to inappropriate antibiotic use and avoidable harm. This Belgian consensus-based recommendation aims to provide a pragmatic framework for the management of penicillin allergy labels in hospitalized adults (>18 years), with particular emphasis on distinguishing low- to high-risk labels.</p><p><strong>Methods: </strong>Recommendations were developed through a structured, multidisciplinary expert consensus process and are presented as a stepwise clinical algorithm.</p><p><strong>Results: </strong>The recommendations highlight a structured approach to evaluate reactions through a series of questions, delineating between severe and non-severe signs. It offers a pragmatic algorithm for managing low-risk penicillin allergy labels through re-administration procedures while ensuring emergency preparedness for rare adverse reactions. Comparisons with existing protocols revealed differences in approaches to delabeling, referral criteria for allergy evaluation, and liberalization of antibiotic choices based on reaction severity, timelines, and individual patient risk factors. The recommendation favors a patient-centric risk-assessment approach, offering distinctions between severe and non-severe reactions and includes precautions based on reaction types and timelines.</p><p><strong>Conclusion: </strong>This consensus-based recommendation offers a structured approach to managing penicillin allergy labels in hospitalized adults.</p>","PeriodicalId":48865,"journal":{"name":"Acta Clinica Belgica","volume":" ","pages":"1-14"},"PeriodicalIF":1.4,"publicationDate":"2026-07-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148585823","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impact of telomere length alteration in chronic kidney disease patients of Pakistan: a case-control study and meta-analysis of 24,089 patients.","authors":"Minahil Tahir, Afrose Liaquat, Fareeha Khalil, Zuha Tariq, Arham Javed, Aleezay Irfan, Muhammad Jawad Khan","doi":"10.1080/17843286.2026.2627250","DOIUrl":"10.1080/17843286.2026.2627250","url":null,"abstract":"<p><strong>Background: </strong>Chronic kidney disease (CKD) is becoming a global health concern due to its rising prevalence owing to the complex interplay of environmental, genetic, and epigenetic factors. Leukocyte telomere length (LTL) is a potential indicator of biological age in age-related diseases. Our objective is to investigate the association between LTL and CKD in Pakistani population to systematically synthesize existing evidence by investigating previously reported studies.</p><p><strong>Material and methods: </strong>We conducted a case-control study (<i>n</i> = 166), aged 18-60 years. Relative LTL was measured using quantitative real-time PCR and expressed as telomere-to-single copy gene (T/S) ratios. Biochemical parameters and estimated glomerular filtration rate (eGFR) were assessed using standard methods. Multivariable linear regression adjusted for demographic and cardiometabolic factors was performed. A meta-analysis (11 studies, <i>n</i> = 24,089) were conducted.</p><p><strong>Results: </strong>Our results revealed significant LTL attrition in CKD patients compared to controls with a moderate effect size. Correlational analysis revealed that LTL positively correlated with eGFR (p-value = 0.038) and negatively correlated with urea and creatinine (<i>p</i> < 0.05). After adjustment for age, sex, body mass index, diabetes, smoking, hypertension, and LDL cholesterol, CKD status remained independently associated with shorter LTL. Meta-analysis demonstrated an overall trend toward shorter telomeres in CKD, although substantial heterogeneity and evidence of small study effects were observed. Subgroup analysis in Asian populations showed a consistent but less robust association.</p><p><strong>Conclusion: </strong>LTL is associated with CKD, which may reflect systemic biological aging and disease burden rather than serving as a standalone clinical biomarker. Longitudinal studies are required to clarify causality and population-specific effects.</p>","PeriodicalId":48865,"journal":{"name":"Acta Clinica Belgica","volume":" ","pages":"195-213"},"PeriodicalIF":1.4,"publicationDate":"2026-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146203467","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Electronic tools to facilitate medication review in nursing homes: a pilot study.","authors":"Marie Carrein, Andreas Capiau, Els Mehuys, Mirko Petrovic, Annemie Somers, Koen Boussery","doi":"10.1080/17843286.2026.2641098","DOIUrl":"10.1080/17843286.2026.2641098","url":null,"abstract":"<p><strong>Objectives: </strong>Medication reviews (MRs) in nursing homes (NHs) are valuable but time-consuming. Electronic screening tools can assist community pharmacists by detecting potential drug-related problems (pDRPs). This study aimed to evaluate the implementation of electronic tools (GheOP³S-tool and EBMeDS®CMR) to facilitate MR in NH residents and to explore the overall clinical and economic impact of this MR process.</p><p><strong>Methods: </strong>A pilot study was conducted in one NH (January-July 2024). For each included resident (life expectancy of ≥3 months, excluding short-stays and general practitioner (GP) refusals), a 3-step MR was performed: 1) medication record analysis by a pharmacist using GheOP³S-tool and EBMeDS®CMR, and additional implicit screening, 2) interdisciplinary meeting (with pharmacist, GP, nurse) to discuss pDRPs and interventions, and 3) 3-month follow-up. Primary outcomes included the number, type, and resolution rate of pDRPs per screening method. Secondary outcomes were changes in medication use (number, fall risk-increasing drugs (FRIDs), Drug Burden Index (DBI)), and medication costs.</p><p><strong>Results: </strong>Fifty-four residents were included (mean age 84.7 ± 8.9 years, 66.7% female). The electronic tools detected 508 pDRPs: 41.7% only by GheOP³S-tool, 29.5% only by EBMeDS®CMR, and 28.7% by both. The pharmacist appended 252 pDRPs. Of the 603 recommendations formulated, 48.4% were accepted and 37.5% implemented. The overall resolution rate was 40.1%. At follow-up, significant reductions were observed in number of medications, FRIDs, DBI, and medication costs.</p><p><strong>Conclusion: </strong>GheOP³S-tool and EBMeDS®CMR detected a considerable proportion of complementary pDRPs. A substantial part of pDRPs was appended by the pharmacist, highlighting the importance of combining explicit and implicit screening.</p>","PeriodicalId":48865,"journal":{"name":"Acta Clinica Belgica","volume":" ","pages":"269-279"},"PeriodicalIF":1.4,"publicationDate":"2026-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147379306","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical characteristics and lipid management of patients with familial hypercholesterolemia: results from a 7 years single-centre experience.","authors":"Amber Vanhulle, Dilara Yurdaer, Lynn van Calster, Anne-Marie Willems, Veronique Moerman, Johan De Sutter","doi":"10.1080/17843286.2026.2638804","DOIUrl":"10.1080/17843286.2026.2638804","url":null,"abstract":"<p><strong>Objectives: </strong>Familial hypercholesterolemia (FH) markedly increases the risk of premature atherosclerotic cardiovascular disease (ASCVD). Despite available therapies, FH remains underdiagnosed and undertreated. The aim of this study is to characterize FH patients and to evaluate treatment response specifically in those with a confirmed pathogenic mutation.</p><p><strong>Methods: </strong>We retrospectively analysed 189 adults with clinical suspicion of FH seen at a cardiology department of a Belgian hospital between 2018 and 2024. Clinical, biochemical, and treatment data were retrieved from electronic records, and the Dutch Lipid Clinic Network (DLCN) score was calculated. Genetic testing was performed in 181 patients. Patients were stratified into primary and secondary prevention groups.</p><p><strong>Results: </strong>The cohort comprised 116 patients (61%) in primary prevention and 73 (39%) in secondary prevention; the latter were older, predominantly male, and had more comorbidities. Genetic mutations were identified in 91 patients, most frequently in the LDL receptor gene (74%), followed by the ApoB gene (19%). Twenty-one patients had a DLCN score > 8, of whom four had no detectable pathogenic mutation. In genetically confirmed FH, mean LDL-cholesterol decreased from 267 ± 82 mg/dL at baseline to 100 ± 57 mg/dL at last follow-up, with greater reductions in secondary prevention. PCSK9 inhibitor use increased significantly during follow-up. Nevertheless, only 43% of secondary prevention patients achieved LDL-C < 55 mg/dL, and 24% of primary prevention patients reached < 70 mg/dL.</p><p><strong>Conclusion: </strong>FH lipid management in this real-world cohort achieved substantial LDL-C reductions, but target attainment remained suboptimal.</p>","PeriodicalId":48865,"journal":{"name":"Acta Clinica Belgica","volume":" ","pages":"234-242"},"PeriodicalIF":1.4,"publicationDate":"2026-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147322395","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Obinutuzumab for membranous nephropathy: a systematic review using pooled case-level extraction analysis.","authors":"İlker Atay, Erhan Eroz, Berfu Korucu, Mehmet Asi Oktan, Yelda Deligoz Bildaci, Serpil Muge Deger, Caner Cavdar, Cihan Heybeli","doi":"10.1080/17843286.2026.2642796","DOIUrl":"10.1080/17843286.2026.2642796","url":null,"abstract":"<p><strong>Background: </strong>Obinutuzumab has increasingly been used in patients with PLA2R-associated membranous nephropathy (MN). However, reported outcomes vary substantially across studies due to heterogeneity in patient selection, response definitions, and follow-up duration. This study aimed to synthesize case-level extraction analysis to better characterize response patterns and factors influencing remission rates.</p><p><strong>Methods: </strong>MEDLINE, Web of Science, SCOPUS, and grey literature were systematically searched. Case-level extraction analysis from eligible case reports and case series were synthesized to evaluate clinical and immunological remission.</p><p><strong>Results: </strong>Eighty-nine patients from 19 publications were included. Most patients (64%) were reported from China. During a median follow-up of 12 months, overall clinical and immunological remission rates were 83% and 88.7%, respectively. Complete remission was numerically less frequent in patients refractory to prior immunosuppressive therapy compared with those who had previously responded (23.5% vs. 61.5%; nominal <i>p</i> = 0.012). Clinical remission appeared more common among patients followed for at least 12 months (92.6% vs. 75%; nominal <i>p</i> = 0.026). Geographic variation in reported outcomes was noted and appeared to be influenced by differences in follow-up duration and publication type. Adverse events were inconsistently reported; when reported, they were predominantly mild to moderate.</p><p><strong>Conclusion: </strong>This descriptive case-level extraction analysis is consistent with previous small series reporting relatively high clinical remission rates for obinutuzumab in PLA2R-associated MN. The observed remission rates may be influenced by prior treatment responsiveness and duration of follow-up.</p>","PeriodicalId":48865,"journal":{"name":"Acta Clinica Belgica","volume":" ","pages":"280-292"},"PeriodicalIF":1.4,"publicationDate":"2026-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147482115","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prevalence of antisynthetase antibodies in a multicentre early rheumatoid arthritis cohort.","authors":"Bram Mariën, Jean-Baptiste Vulsteke, Johan Joly, Silke Willebrords, Minoru Satoh, Xavier Bossuyt, Patrick Verschueren, Ellen De Langhe","doi":"10.1080/17843286.2026.2645165","DOIUrl":"10.1080/17843286.2026.2645165","url":null,"abstract":"<p><strong>Objectives: </strong>To assess the prevalence of anti-aminoacyl tRNA synthetase antibodies (anti-ARS) in a large cohort of untreated early rheumatoid arthritis (RA) patients compared to healthy controls.</p><p><strong>Methods: </strong>The baseline serum samples of patients with early RA (<i>n</i> = 332) included in the multicentre CareRA trial, a completed interventional trial in untreated early RA, and healthy controls (<i>n</i> = 72) were screened for anti-ARS antibodies with a commercial dot immunoassay (DIA). Radiolabelled protein immunoprecipitation (IP) was performed to confirm the presence of suspected anti-ARS antibodies, in addition to HEp-2 indirect immunofluorescence and a commercial line immunoassay (LIA).</p><p><strong>Results: </strong>Anti-ARS antibodies (anti-PL12 <i>n</i> = 2, anti-OJ <i>n</i> = 1) were detected in 0.9% of early RA patients using a DIA, of which one anti-PL12-positive sample was also positive on LIA. Presence of these anti-ARS antibodies could, however, not be confirmed by protein immunoprecipitation. No anti-ARS antibodies were detected in the healthy control group.</p><p><strong>Conclusion: </strong>We report that the presence of anti-ARS antibodies cannot be confirmed by IP in a multicentre cohort of untreated early RA patients. Anti-ARS autoantibodies should not routinely be evaluated in patients with early RA. Sensitivity and specificity issues with DIA and LIA for anti-ARS should be considered in the interpretation of anti-ARS testing.</p>","PeriodicalId":48865,"journal":{"name":"Acta Clinica Belgica","volume":" ","pages":"188-194"},"PeriodicalIF":1.4,"publicationDate":"2026-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147500426","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}